RLYB
Rallybio Corporation
There isn't enough reported data to score RLYB yet.
RLYB Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Stable | |
| Strong | |
| Unavailable |
RLYB's cash flow is currently strong, and its profitability is stable, but its revenue is weak. There isn't enough data to rate its balance sheet.
RLYB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 2.1x | $9.58 | -39% |
| Fair | 2.1x | $9.76 | -38% |
| Expensive | 2.9x | $13.40 | -14% |
| Current | 3.4x | $15.65 | — |
Historical ranges are pointers, not guarantees.
RLYB's PE is 3.4x, but its earnings don't support one, so it isn't a reliable read right now.
RLYB Forward outlook
There aren't enough analyst estimates for RLYB to show an outlook.
RLYB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $4.56 | +$6.96 |
| Q2 2026 | $7.92 | +$15.28 |
| Q1 2026 | -$1.37 | +$7.19 |
| Q4 2025 | -$1.59 | +$9.05 |
| Q3 2025 | -$2.40 | +$10.40 |
| Q2 2025 | -$7.36 | +$6.96 |
| Q1 2025 | -$8.56 | +$6.48 |
| Q4 2024 | -$10.64 | +$4.08 |
RLYB has returned to profit: it earned $4.56 per share over the past year, after losing money the year before.
RLYB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $212K | 0% |
| Q4 2025 | $222K | +11000% |
| Q3 2025 | $212K | -29% |
| Q2 2025 | $212K | -29% |
RLYB's revenue has slid since its 2024 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -4119% | +442 points |
| Q4 2025 | -2888% | +577512 points |
| Q3 2025 | -3267% | +769 points |
| Q2 2025 | -4744% | +953 points |
| Q1 2025 | -4561% | N/A |
| Q4 2024 | -580400% | N/A |
| Q3 2024 | -4035% | N/A |
| Q2 2024 | -5697% | N/A |
RLYB's operating margin was −4119% last quarter, up 442 points from the same quarter a year ago.
RLYB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.3M | +$4.3M |
| Q2 2026 | $45.9M | +$54.3M |
| Q1 2026 | -$8M | +$2.2M |
| Q3 2025 | -$6.6M | +$7M |
| Q2 2025 | -$8.4M | +$2M |
| Q1 2025 | -$10.2M | +$5.3M |
| Q3 2024 | -$13.5M | +$2.9M |
| Q2 2024 | -$10.4M | +$3M |
RLYB's free cash flow has turned positive after five years mostly in the red: $31M over the past year.
RLYB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.4% | -82.9K shares |
| 1 year | +1.5% | +82.7K shares |
| 3 years | +13% | +649K shares |
| 5 years | +1049% | +5.2M shares |
| Available history | +106% | +2.9M shares |
RLYB has 6M diluted shares, up 1.5% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
RLYB Net Leverage
RLYB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.4 | Neutral |
| Stochastic | 17.7 | Oversold |
RLYB's weekly RSI is 54 (neutral) and its Stochastic is 18 (oversold).
RLYB PE vs Healthcare Sector
| Metric | RLYB | Sector median | Relative |
|---|---|---|---|
| PE | 3.4x | 26x | 87% below |
RLYB is trading at 3.4x earnings, a 87% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
RLYB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $16.3 | 4.1% below |
| 20 week MA | $16.4 | 4.7% below |
| 50 week MA | $12.1 | 29% above |
| 100 week MA | $8.34 | 88% above |
| 200 week MA | $17.4 | 10% below |
RLYB's trend is mixed: it's above two of its five weekly moving averages, and 10% below its 200-week average.
RLYB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $136.0 | $91.6 | -33% |
| 2022 | $91.6 | $46.0 | -50% |
| 2023 | $46.0 | $19.1 | -58% |
| 2024 | $19.1 | $7.31 | -62% |
| 2025 | $7.31 | $5.50 | -25% |
| 2026 YTD | $5.50 | $15.7 | +185% |
RLYB has finished every year since 2021 lower, and it's up 185% so far in 2026.